In another phase 1 trial, another recombinant HER2 protein with adjuvant AS15 was administered to 61 trastuzumab-naive patients with stage II-III HER2-overexpressing breast cancer after surgical resection and adjuvant therapy (122). This evidence concerns the gene ERBB2 and breast carcinoma.